ClinicalTrials.gov
public full text
Public Domain
Urate Lowering Therapies and Left Ventricular Diastolic Dysfunction
Hyperuricemia is an additional risk factor for cardiovascular disease, associating with left ventricular diastolic dysfunction in individuals with metabolic syndrome. The effect of urate-lowering therapies on left ventricular diastolic dysfunction remains unclear. The study is conducted to investigate whether febuxostat or benzbromarone might improve left ventricular diastolic dysfunction in individuals with metabolic syndrome and hyperuricemia
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- The Relationship Among, Serum Uric Acid, Left Ventricular Hypertrophy and Metabolic Syndrome#1349814
- Febuxostat, Blood Pressure and the Intrarenal Renin-Angiotensin System (RAS)#1365112
- Effects of Hyperuricemia Reversal on Features of the Metabolic Syndrome#833812
- Metabolic Modulation as Treatment in Acute Heart Failure#1008399
- Biomarkers and Risk Prediction in Cardiovascular-Kidney-Metabolic Syndrome: A Comprehensive Review.#1299588
Record · ID 1454264
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive